- Home
- CAAP vs FOLD Comparison
CAAP vs FOLD Comparison
Compare CAAP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- FOLD
- Stock Information
- Founded
- CAAP 1998
- FOLD 2002
- Country
- CAAP Luxembourg
- FOLD United States
- Employees
- CAAP N/A
- FOLD N/A
- Industry
- CAAP Aerospace
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- FOLD Health Care
- Exchange
- CAAP Nasdaq
- FOLD Nasdaq
- Market Cap
- CAAP 3.3B
- FOLD 2.9B
- IPO Year
- CAAP 2018
- FOLD 2007
- Fundamental
- Price
- CAAP $20.32
- FOLD $5.87
- Analyst Decision
- CAAP Strong Buy
- FOLD Buy
- Analyst Count
- CAAP 2
- FOLD 10
- Target Price
- CAAP $23.60
- FOLD $16.22
- AVG Volume (30 Days)
- CAAP 121.5K
- FOLD 5.4M
- Earning Date
- CAAP 08-20-2025
- FOLD 08-07-2025
- Dividend Yield
- CAAP N/A
- FOLD N/A
- EPS Growth
- CAAP N/A
- FOLD N/A
- EPS
- CAAP 1.05
- FOLD N/A
- Revenue
- CAAP $1,858,038,000.00
- FOLD $543,141,000.00
- Revenue This Year
- CAAP N/A
- FOLD $19.84
- Revenue Next Year
- CAAP $12.97
- FOLD $23.18
- P/E Ratio
- CAAP $19.09
- FOLD N/A
- Revenue Growth
- CAAP 28.46
- FOLD 28.25
- 52 Week Low
- CAAP $13.97
- FOLD $5.51
- 52 Week High
- CAAP $22.13
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- CAAP 54.26
- FOLD 36.57
- Support Level
- CAAP $19.38
- FOLD $5.51
- Resistance Level
- CAAP $20.28
- FOLD $5.82
- Average True Range (ATR)
- CAAP 0.48
- FOLD 0.19
- MACD
- CAAP 0.01
- FOLD -0.01
- Stochastic Oscillator
- CAAP 79.43
- FOLD 25.00
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.